Literature DB >> 2179035

Infrequent point mutations of ras oncogenes in gastric cancers.

D M Nanus1, D P Kelsen, I R Mentle, N Altorki, A P Albino.   

Abstract

Adenocarcinomas of the proximal and distal stomach have significant clinical and biological differences. A study was undertaken to determine if a difference in the incidence of mutated ras oncogenes exists between proximal (gastroesophageal junction or cardia) and distal (body or antrum) gastric tumors, and to assess the overall incidence in gastric cancers from non-Asian patients. Deoxyribonucleic acid from 28 primary gastric adenocarcinomas were analyzed for point mutations in codons 12, 13, and 61 of the Ha-ras, Ki-ras, and N-ras protooncogenes using polymerase-catalyzed chain reaction methodology. Twelve tumors were located at the gastroesophageal junction or cardia, and 16 in the body or antrum. Mutated ras genes were detected in 2 of 28 tumors for an overall incidence of 7%. The mutations occurred in codon 61 of the N-ras gene in a proximal gastric cancer and in codon 12 of the Ki-ras gene in a distal gastric cancer. These data indicate that mutations in ras genes are an uncommon event in primary gastric cancers and that there is no meaningful difference in the incidence of ras mutations in proximal and distal stomach cancers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179035     DOI: 10.1016/0016-5085(90)90019-w

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer.

Authors:  Yoshichika Oishi; Yoshiyuki Watanabe; Yoshihito Yoshida; Yoshinori Sato; Tetsuya Hiraishi; Ritsuko Oikawa; Tadateru Maehata; Hiromu Suzuki; Minoru Toyota; Hirohumi Niwa; Michihiro Suzuki; Fumio Itoh
Journal:  Tumour Biol       Date:  2011-12-08

2.  Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes.

Authors:  Yoshiyuki Watanabe; Hyun Soo Kim; Ryan J Castoro; Woonbok Chung; Marcos R H Estecio; Kimie Kondo; Yi Guo; Saira S Ahmed; Minoru Toyota; Fumio Itoh; Ki Tae Suk; Mee-Yon Cho; Lanlan Shen; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Gastroenterology       Date:  2009-04-16       Impact factor: 22.682

3.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

4.  The role of ras gene mutation in gastric cancer and precancerous lesions.

Authors:  Y Hao; J Zhang; Y Lu; C Yi; W Qian; J Cui
Journal:  J Tongji Med Univ       Date:  1998

Review 5.  Anti-HER agents in gastric cancer: from bench to bedside.

Authors:  Lorenzo Fornaro; Maurizio Lucchesi; Chiara Caparello; Enrico Vasile; Sara Caponi; Laura Ginocchi; Gianluca Masi; Alfredo Falcone
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

Review 6.  Advances of Molecular Targeted Therapy in Gastric Cancer.

Authors:  Bulent Cetin; Ozge Gumusay; Mustafa Cengiz; Ahmet Ozet
Journal:  J Gastrointest Cancer       Date:  2016-06

7.  Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

Authors:  Hilda Wong; Thomas Yau
Journal:  Oncologist       Date:  2012-02-14

Review 8.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

9.  Loss of heterozygosity and K-ras gene mutations in gastric cancer.

Authors:  G N Ranzani; B Renault; N S Pellegata; P Fattorini; E Magni; F Bacci; D Amadori
Journal:  Hum Genet       Date:  1993-10-01       Impact factor: 4.132

10.  Absence of ras gene mutations in early gastric carcinomas.

Authors:  M E Craanen; P Blok; B Top; L Boerrigter; W Dekker; G J Offerhaus; G N Tytgat; S Rodenhuis
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.